wire - news in brief

« BACK

Health



Results 51 - 100 of 1695.


Pharmacology - Health - 08.03.2019
European Commission approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Approval based on significant survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (N

Health - Pharmacology - 07.03.2019
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc.

Pharmacology - Health - 07.03.2019
Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Combination was granted Breakthrough Therapy Designation, the fifth for Venclexta Roche today announced the submiss

Pharmacology - Health - 05.03.2019
Novartis Cosentyx shows superior improvements in psoriasis patients’ quality of life versus Janssen’s IL-23 Stelara *
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared to Stelara * (68.4% versus 55.9%, respectively) Results from CLARITY study presented in 2018 showed Cosentyx was significantly more effective than Stelara * in delivering clear and almost clear skin at 12 and 16 weeks.

Pharmacology - Health - 28.02.2019
FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta? (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment

Health - Physics - 28.02.2019
Children are her passion
At the Paul Scherrer Institute PSI, Beate Timmermann built up a programme providing proton therapy for children with cancer at the same time she was raising her own son.

Life Sciences - Health - 27.02.2019
Model redefines the tree of life as we know it
Model redefines the tree of life as we know it
A new method shows that the relationships between living species, from bacteria to plants and animals, are different from previous estimates.

Health - Life Sciences - 27.02.2019
Bern Center for Precision Medicine founded
Bern Center for Precision Medicine founded
Precision medicine "tailored" to individual patients is regarded as the medicine of the future. It is already being practiced at the University of Bern and Inselspital, Bern University Hospital.

Pharmacology - Health - 25.02.2019
Roche enters into definitive merger agreement to acquire Spark Therapeutics
Roche to acquire Spark Therapeutics for US$ 114.50 per share Spark Therapeutics is a leader in discovering, developing and delivering gene therapies with one commercial asset and four programm

Pharmacology - Health - 19.02.2019
FDA grants priority review to Roche’s polatuzumab vedotin in previously treated aggressive lymphoma
Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns Polatuzumab vedotin has shown significant potential to improve outcomes

Pharmacology - Health - 19.02.2019
FDA grants Priority Review to Roche’s personalised medicine entrectinib
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and

Health - Business / Economics - 14.02.2019

Pharmacology - Health - 13.02.2019
Novartis receives FDA approval for Egaten for the treatment of fascioliasis, a neglected tropical disease
Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO Fascioliasis, commonly known as liver fluke infes

Innovation / Technology - Health - 07.02.2019
Lunaphore, an EPFL spin-off, brings its first product to market
Lunaphore, an EPFL spin-off, brings its first product to market
The first rapid screening test for cancer developed by EPFL spin-off Lunaphore is being released today.

Pharmacology - Health - 05.02.2019
Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche's application is being reviewed under the US FDA's Real-Time Oncology Review and Assessment Aid pilot programmes Kadcyla was granted Breakthrough Therapy Designation for this application Ro

Pharmacology - Health - 01.02.2019
CHMP recommends EU approval of Roche’s Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer
Recommendation based on the Phase III IMpower150 study which showed that Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy (paclitaxel and carboplatin) helped people

Pharmacology - Health - 01.02.2019
CHMP recommends EU approval of Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis in a prospective intra-patient comparison First new class of medicine in nearly 20 years for people wit

Pharmacology - Health - 30.01.2019
Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer’s disease (AD) - other company programmes in AD continue
At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0% treated with Her

Innovation / Technology - Health - 29.01.2019
Implants from the 3D printer
3D printing is finding its way into industrial manufacturing. This technology and the increasing digitalization of design and manufacturing processes - keyword "Industry 4.0" - will also play a central role in medical technology in the future. A new technology transfer centre in the canton of Solothurn will help to transfer know-how from science to industry - and at the same time accelerate research.

Health - Life Sciences - 22.01.2019

Pharmacology - Health - 17.01.2019
FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Tecentriq (atezolizumab) in combination with Abra

Health - Materials Science - 15.01.2019
Ears from the 3D-printer
Ears from the 3D-printer
Cellulose obtained from wood has amazing material properties. Empa researchers are now equipping the biodegradable material with additional functionalities to produce implants for cartilage diseases using 3D printing.

Health - Life Sciences - 15.01.2019

Pharmacology - Health - 08.01.2019
Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease Sickle cell VOCs, which are triggered

Pharmacology - Health - 07.01.2019
Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder
ReSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder Cleared by the FDA in December, reSET-O is available immediately As part of a broader f

Innovation / Technology - Health - 04.01.2019

Health - Pharmacology - 21.12.2018
Novartis receives European Commission (EC) approval for expanded indication for Kisqali (ribociclib)
Basel, December 21, 2018 - Novartis today announced that the European Commission (EC) approved an expanded indication for Kisqali (ribociclib), the CDK4/6 inhibitor with the largest body of first-li

Pharmacology - Health - 20.12.2018
Novartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapies
Proposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis leading CAR-T cell therapy Kymriah (tisagenlecleucel) and recent successful completion of tec

Health - Pharmacology - 17.12.2018
PRIME designation granted by European Medicines Agency for Roche’s risdiplam for treatment of spinal muscular atrophy (SMA)
PRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the treatment

Environment - Health - 14.12.2018

Pharmacology - Health - 10.12.2018
Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder
ReSET-O TM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder Pear Therapeutics is leading the development of a new therapeutic class with two FDA-a

Health - Pharmacology - 08.12.2018
Novartis data demonstrates consistent efficacy and tolerability of Kisqali combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine therapy

Pharmacology - Health - 07.12.2018
FDA approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Approval based on survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with n

Health - Pharmacology - 05.12.2018
Roche’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0% treated with Her

Pharmacology - Health - 05.12.2018
FDA grants priority review to Roche’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizum

Pharmacology - Health - 04.12.2018
Novartis advances ligelizumab (QGE031) in urticaria to Phase III on basis of strong Phase II head-to-head data
PEARL 1 and PEARL 2, the largest pivotal trials to date in chronic spontaneous urticaria (CSU), will enroll more than 2,000 CSU patients , Ligelizumab (QGE031), a monoclonal antibody, is being deve

Pharmacology - Health - 04.12.2018
New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
New analyses from the phase III MURANO study in previously treated chronic lymphocytic leukaemia show continued benefit from fixed-duration regimen after a median follow-up of three years Updated res

Pharmacology - Health - 03.12.2018
Roche’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors
Nearly 77% of children receiving Hemlibra once weekly experienced zero treated bleeds Hemlibra once weekly reduced treated bleeds by 99% compared to prior bypassing agents in a prospective intra-pati